Management of castration-resistant prostate cancer: bisphosphonates and emerging therapies. Issue 12 (December 2010)

• Record Type: Journal Article
• Authors: Saad, Fred; Colombel, Marc
• Is Part Of: Expert review of anticancer therapy. Volume 10:Issue 12(2010)
• Page Start: 1991
• Page End: 2002
• Publication Date: 2010-12
• Subjects: bisphosphonate -- bone metastases -- prostate cancer -- skeletal-related events -- survival -- zoledronic acid; Cancer -- Treatment -- Periodicals; 616.99406
• DOI: 10.1586/era.10.191
• Languages: English
• ISSNs: 1473-7140

Abstract

Approximately 70% of patients with prostate cancer will develop bone metastases that often lead to bone pain and skeletal-related events. Several bisphosphonates have shown promising activity for palliating pain. Only zoledronic acid has significantly delayed the onset and reduced the incidence of skeletal-related events in men with castration-resistant prostate cancer. In addition, studies suggest that bisphosphonates have anticancer activity that may prevent disease progression and improve survival. Clodronate was shown to improve survival in a study of men with metastatic androgen-sensitive prostate cancer. Emerging therapies are being investigated for their ability to maintain bone health. The findings presented herein highlight the importance of bone-targeted therapies for patients with bone metastases from prostate cancer.